Penetrating the Blood–Brain Barrier to Treat EGFR-Mutated NSCLC With CNS Metastases
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
AZD3759, a BBB-Penetrating EGFR Inhibitor for the Treatment of EGFR Mutant NSCLC With CNS Metastases
Sci Transl Med 2016 Dec 07;8(368)368ra172, Z Yang, Q Guo, Y Wang, K Chen, L Zhang, Z Cheng, Y Xu, X Yin, Y Bai, S Rabbie, DW Kim, MJ Ahn, JC Yang, X ZhangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.